In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TransVascular: Re-Tooling After Clinical Failure

Executive Summary

After a major setback in clinical trials of a lead product, many start-ups fail. But TransVascular Inc. has not only survived, it is starting clinical trials with a revised device and developing new applications for its technology. The TransAccess System, the company's core technology, is a coronary revascularization device that ran into problems when its trial was discontinued due to severe adverse coronary events. Transvascular believes it found the problem and has developed a solution--a better guidance system and blocking device. Now, its new PICVA system is scheduled to be used shortly on several patients in Europe.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts